Skip to Main Content
1-877-YALEMDS
1-877-YALEMDS
Phase III

An Open-label, Randomized, Multicenter Phase III Clinical Trial of SHR-A1811 Versus Investigator-selected Chemotherapy for Platinum-resistant Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  • Study HIC#:2000039498
  • Last Updated:09/14/2025

This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.

    Contact Us

    For more information about this study, including how to volunteer, contact:

    Carl Brown

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

    CREATE A VOLUNTEER PROFILE

    Eligibility Criteria

    Inclusion Criteria:

    1. The subjects voluntarily joined the study and signed the Informed consent forms (ICF).
    2. Measurable disease, as defined by RECIST v1.1.
    3. The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1.
    4. Life expectancy ≥ 12 weeks.

    Exclusion Criteria:

    1. Symptomatic, untreated or active central nervous system metastases.
    2. Have uncontrolled or severe cardiovascular disease.
    3. With any active autoimmune disease or history of autoimmune disease.
    4. Patients with active hepatitis B or hepatitis C.
    5. Severe infections prior to initiation of study treatment.
    6. Patients with active tuberculosis.

    Principal Investigator

    Sub-Investigators

    For more information about this study, including how to volunteer, contact:

    Carl Brown